MeiraGTx Holdings plc Fair Value of Assets Acquired
MeiraGTx Holdings plc (MGTX) reported Fair Value of Assets Acquired of $3.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueOfAssetsAcquired · last filed 2026-08-13
- MeiraGTx Holdings plc fair value of assets acquired for the quarter ending 2023-06-30 was -$777.00K.
- MeiraGTx Holdings plc fair value of assets acquired for the quarter ending 2023-03-31 was $3.16M, a 63.09% decline year-over-year.
- MeiraGTx Holdings plc fair value of assets acquired for the quarter ending 2022-12-31 was -$492.00K, a 115.61% decline year-over-year.
- MeiraGTx Holdings plc fair value of assets acquired for the quarter ending 2022-09-30 was $114.00K, a 86.48% decline year-over-year.
- MeiraGTx Holdings plc fair value of assets acquired for fiscal 2022 was $7.11M, a 1.00% decline from fiscal 2021.
- MeiraGTx Holdings plc fair value of assets acquired for fiscal 2021 was $7.18M, a 344.46% increase from fiscal 2020.
- MeiraGTx Holdings plc fair value of assets acquired for fiscal 2020 was $1.61M, a 6.29% increase from fiscal 2019.
- MeiraGTx Holdings plc fair value of assets acquired for fiscal 2019 was $1.52M, a 418.49% increase from fiscal 2018.
| Period end | Fair Value of Assets Acquired 3 month | Fair Value of Assets Acquired 3 month as first filed | Fair Value of Assets Acquired 6 month | Fair Value of Assets Acquired 6 month as first filed | Fair Value of Assets Acquired 9 month | Fair Value of Assets Acquired 9 month as first filed | Fair Value of Assets Acquired 12 month | Fair Value of Assets Acquired 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.26M 10-Q · filed 2026-08-13 | |||||||
| 2023-06-30 | -$777.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.38M 10-Q · filed 2023-08-10 | $1.89M derived: sum of 3 quarters · filed 2023-08-10 | $2.01M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2023-03-31 | $3.16M 10-Q · filed 2023-05-11 | $2.67M derived: sum of 2 quarters · filed 2023-05-11 | $2.78M derived: sum of 3 quarters · filed 2023-05-11 | $1.70M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-12-31 | -$492.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$378.00K derived: sum of 2 quarters · filed 2023-03-14 | -$1.46M derived: sum of 3 quarters · filed 2023-08-10 | $7.11M 10-K · filed 2023-03-14 | ||||
| 2022-09-30 | $114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$969.00K derived: sum of 2 quarters · filed 2023-08-10 | $7.60M 10-Q · filed 2022-11-10 | $10.75M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $7.48M 10-Q · filed 2023-08-10 | $10.63M derived: sum of 3 quarters · filed 2023-08-10 | $11.48M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $8.57M 10-Q · filed 2023-05-11 | $11.72M derived: sum of 2 quarters · filed 2023-05-11 | $12.56M derived: sum of 3 quarters · filed 2023-05-11 | $14.04M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $3.99M derived: sum of 2 quarters · filed 2023-03-14 | $5.47M derived: sum of 3 quarters · filed 2023-03-14 | $7.18M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $843.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.32M derived: sum of 2 quarters · filed 2022-11-10 | $4.03M 10-Q · filed 2022-11-10 | $4.45M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.18M 10-Q · filed 2022-08-11 | $3.61M derived: sum of 3 quarters · filed 2022-08-11 | $4.64M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.71M 10-Q · filed 2022-05-12 | $2.13M derived: sum of 2 quarters · filed 2022-05-12 | $3.16M derived: sum of 3 quarters · filed 2022-05-12 | $819.00K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.45M derived: sum of 2 quarters · filed 2022-03-10 | -$890.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.61M 10-K · filed 2022-03-10 | $1.62M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.31M derived: sum of 2 quarters · filed 2021-11-10 | $1.19M 10-Q · filed 2021-11-10 | $1.19M 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | -$2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $161.00K 10-Q · filed 2021-08-11 | $161.01K 10-Q · filed 2020-08-06 | |||||
| 2020-03-31 | $2.50M 10-Q · filed 2021-05-11 | $2.51M 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | $1.52M 10-K · filed 2021-03-11 | |||||||
| 2019-06-30 | -$165.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $71.47K 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $236.53K 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $293.05K 10-K · filed 2020-03-11 | |||||||
| 2018-06-30 | $298.55K 10-Q · filed 2018-08-08 | |||||||
| 2017-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$1.15M derived: sum of 2 quarters · filed 2019-03-26 | $415.65K 10-K · filed 2019-03-26 | |||||
| 2017-09-30 | $79.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.64M 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | $1.56M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |